Penghambat Reseptor Angiotensin Neprilysin (ARNi): Artikel Tinjauan
Abstract
Angiotensin receptor neprilysin inhibitor (ARNi) saat ini digunakan untuk pengobatan gagal jantung dengan penurunan fraksi ejeksi (HFrEF). Selain gagal jantung, obat golongan ARNi telah banyak diteliti potensinya untuk menangani berbagai kondisi penyakit. Sacubitril/valsartan merupakan obat golongan ARNi pertama yang disetujui oleh FDA. Penelitian ini adalah studi literatur yang dilakukan dengan mengumpulkan jurnal ilmiah menggunakan kata kunci “angiotensin receptor-neprilysin inhibitor (ARNi)”, “sacubitril/valsartan”, “heart failure”, “hypertension” menggunakan mesin pencarian Google Scholar dan PubMed dalam rentang waktu 10 tahun terakhir. Hasil yang diperoleh yaitu kombinasi mekanisme kerja dari obat ini telah menunjukkan manfaat klinis yang signifikan dalam pengobatan berbagai penyakit kardiovaskular. Studi klinis menunjukkan efikasi ARNi dalam mengurangi morbiditas dan mortalitas pada pasien dengan HFrEF, serta berpotensi untuk menangani berbagai kondisi kardiovaskular lainnya seperti hipertensi, infark miokardium, dan aritmia. Namun, beberapa efek samping seperti hipotensi, hiperkalemia, dan angioedema mungkin dapat terjadi sehingga dalam pemberian obat ARNi diperlukan pertimbangan berdasarkan karakteristik pasien dan faktor risiko yang terkait, serta pemantauan selama pengobatan.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. Hypertens Res [Internet]. 2021 [cited 2024 Sep 17];44(10):1239–50.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med [Internet]. 2014;371(11):993–1004.
Nordberg Backelin C, Fu M, Ljungman C. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Fail [Internet]. 2020;7(3):1049–55.
Kario K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): Potential uses in hypertension, heart failure, and beyond. Curr Cardiol Rep [Internet]. 2018;20(1):5.
Eadie AL, Brunt KR, Herder M. Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan). Pharmacol Res Perspect [Internet]. 2021;9(3):e00794.
Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev [Internet]. 2019;24(2):167–176.
Fonseca C, Brito D, Ferreira J, Franco F, Morais J, Silva Cardoso J, et al. Sacubitril/valsartan: A practical guide. Rev Port Cardiol (Engl Ed) [Internet]. 2019;38(5):309–13.
U.S. National Library of Medicine. Entresto Film Coated Tablet (Novartis Pharmaceuticals Corporation) [Internet]. https://dailymed.nlm.nih.gov/dailymed/. 2024 [cited 2024 Sep 17]. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/entresto.pdf
Abumayyaleh M, El-Battrawy I, Behnes M, Borggrefe M, Akin I. Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiol [Internet]. 2020;16(4):227–36.
Iborra-Egea O, Gálvez-Montón C, Roura S, Perea-Gil I, Prat-Vidal C, Soler-Botija C, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl [Internet]. 2017;3:12.
Mustafa NH, Jalil J, Zainalabidin S, Saleh MSM, Asmadi AY, Kamisah Y. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Front Pharmacol [Internet]. 2022;13:892460.
Vilela-Martin JF. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Devel Ther [Internet]. 2016;10:1627–39.
Greenberg B. Angiotensin receptor-neprilysin inhibition (ARNI) in heart failure. Int J Heart Fail [Internet]. 2020;2(2):73–90.
Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharmacol Ther [Internet]. 2021;227:107863.
Khder Y, Shi V, McMurray JJV, Lefkowitz MP. Sacubitril/valsartan (LCZ696) in heart failure. Handb Exp Pharmacol [Internet]. 2017;243:133–65.
Pavo IJ, Pavo N, Kastner N, Traxler D, Lukovic D, Zlabinger K, et al. Heart failure with reduced ejection fraction is characterized by systemic NEP downregulation. JACC Basic Transl Sci [Internet]. 2020;5(7):715–26.
Clements RT, Vang A, Fernandez-Nicolas A, Kue NR, Mancini TJ, Morrison AR, et al. Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril/valsartan. Circ Heart Fail [Internet]. 2019;12(11):e005819
Hsu S-J, Huang H-C, Chuang C-L, Chang C-C, Hou M-C, Lee F-Y, et al. Dual angiotensin receptor and neprilysin inhibitor ameliorates portal hypertension in portal hypertensive rats. Pharmaceutics [Internet]. 2020;12(4).
Murphy SP, Prescott MF, Maisel AS, Butler J, Piña IL, Felker GM, et al. Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction. Circ Heart Fail [Internet]. 2021;14(6):e008410.
Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA [Internet]. 2019;322(11):1085–95.
Martín-Garcia A, López-Fernández T, Mitroi C, Chaparro-Muñoz M, Moliner P, Martin-Garcia AC, et al. Effectiveness of sacubitril–valsartan in cancer patients with heart failure. ESC Heart Fail [Internet]. 2020 [cited 2024 Sep 17];7(2):763–7.
Masarone D, Errigo V, Melillo E, Valente F, Gravino R, Verrengia M, et al. Effects of sacubitril/valsartan on the right ventricular arterial coupling in patients with heart failure with reduced ejection fraction. J Clin Med [Internet]. 2020;9(10).
Yenerçağ M, Arslan U, Dereli S, Çoksevim M, Doğduş M, Kaya A. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging [Internet]. 2020;37(1):165–73.
Romano G, Vitale G, Ajello L, Agnese V, Bellavia D, Caccamo G, et al. The effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure with reduced ejection fraction: The “hemodynamic recovery.” J Clin Med [Internet]. 2019;8(12).
Nakou ES, Marketou ME, Patrianakos A, Protonotarios A, Vardas PE, Parthenakis FI. Short-term effects of angiotensin receptor-neprilysin inhibitors on diastolic strain and tissue doppler parameters in heart failure patients with reduced ejection fraction: A pilot trial. Hellenic J Cardiol [Internet]. 2019;61(6):415–8.
Russo V, Bottino R, Rago A, Papa AA, Liccardo B, Proietti R, et al. The effect of sacubitril/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator. J Clin Med [Internet]. 2020;9(4).
Kang D-H, Park S-J, Shin S-H, Hong G-R, Lee S, Kim M-S, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation [Internet]. 2019;139(11):1354–65.
Hu J, Wu Y, Zhou X, Wang X, Jiang W, Huo J, et al. Beneficial effects of sacubitril/valsartan at low doses in an Asian real-world heart failure population. J Cardiovasc Pharmacol [Internet]. 2020;76(4):445–51. Available from: http://dx.doi.org/10.1097/FJC.0000000000000873
Kim HM, Hwang I-C, Choi W, Yoon YE, Cho G-Y. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. Sci Rep [Internet]. 2021;11(1):22342.
Karabulut U, Keskin K, Karabulut D, Yiğit E, Yiğit Z. Effect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction. Angiology [Internet]. 2021;73(4):350–6.
Cada DJ, Baker DE, Leonard J. Sacubitril/valsartan. Hosp Pharm [Internet]. 2015;50(11):1025–36.
Dargad RR, Prajapati MR, Dargad RR, Parekh JD. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor. Indian Heart J [Internet]. 2018;70 Suppl 1(Suppl 1):S102–10.
Ulfa NM. Analisis Efektivitas Kontrol Penurunan Tekanan Darah pada Pasien Hipertensi yang Mendapat Terapi Obat Antihipertensi Golongan Angiotensin Receptor Blocker’s (Candersartan, Valsartan, Kalium Losartan). Pharmasci [Internet]. 2017;2(2):9–14.
Sarwar CMS, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, et al. Hyperkalemia in heart failure. J Am Coll Cardiol [Internet]. 2016;68(14):1575–89.
Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol [Internet]. 2016;14(3):171–86.
Pinto B, Jadhav U, Singhai P, Sadhanandham S, Shah N. ACEI-induced cough: A review of current evidence and its practical implications for optimal CV risk reduction. Indian Heart J [Internet]. 2020 [cited 2024 Sep 17];72(5):345–50.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol [Internet]. 2016;68(13):1476–88.
Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of Heart Failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: A secondary analysis of the PARADIGM-HF trial. JAMA Cardiol [Internet]. 2017;2(1):79–85.
Wang J-G, Yukisada K, Sibulo A Jr, Hafeez K, Jia Y, Zhang J. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens [Internet]. 2017;35(4):877–85.
Zhao Y, Yu H, Zhao X, Ma R, Li N, Yu J. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: A meta-analysis of randomized Controlled Trials. J Cardiovasc Pharmacol Ther [Internet]. 2017;22(5):447–57.
Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (sacubitril/valsartan) on blood pressure in patients with hypertension: A meta-analysis of randomized controlled trials. Cardiology [Internet]. 2020;145(9):589–98.
Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res [Internet]. 2015;38(4):269–75.
Sobiborowicz-Sadowska AM, Kamińska K, Cudnoch-Jędrzejewska A. Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity. Cancers (Basel) [Internet]. 2023;15(1).
Sutanto H, Dobrev D, Heijman J. Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias. Int J Mol Sci [Internet]. 2021
Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi). The Journal of Clinical Pharmacology. 2010 Apr;50(4):401–14.
Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Drug Metabolism and Disposition. 2016 Jan 27;44(4):554–9.
Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, et al. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems [Internet]. 2005 Jun 1;35(6):589–602.
Zhang XJ, Liu CC, Li ZL, Ding L, Zhou Y, Zhang DJ, et al. Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease. Diabetology & Metabolic Syndrome. 2024 Feb 10;16(1).
DOI: https://doi.org/10.15416/ijcp.2024.13.3.54718
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
